Abstract：
Skin and soft tissue infections (SSTIs) are among the most common bacterial infections reported in outpatients. Drug-resistant bacteria are the major cause of treatment failure and increased mortality rate in patients with SSTIs, posing significant challenges to human health. In this study, new-generation rhodium nanoplates (RhNPs) and glycol chitosan- and polydopamine-functionalized RhNPs (Rh@GCS) are developed for the treatment of drug-resistant SSTIs. RhNPs exhibited favorable antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Ag-resistant MRSA. The modified Rh@GCS exhibited enhanced antibacterial activity and can directly kill various drug-resistant bacteria by increasing the permeability of cell membranes, including gram-positive MRSA and gram-negative multidrug-resistant Escherichia coli (E.coli) and Pseudomonas aeruginosa (PA). Moreover, Rh@GCS effectively inhibited bacterial growth and promoted the healing of skin lesions in MRSA-induced SSTI mouse models. These results suggest that Rh@GCS is a promising nonantibiotic antimicrobial agent for the treatment of drug-resistant SSTIs.
摘要：
皮肤和软组织感染（STTI）是门诊患者中最常见的细菌感染。耐药菌是SSTI患者治疗失败和死亡率增加的主要原因,对人类健康构成重大挑战。在这项研究中,新一代铑纳米板（RhNPs）和乙二醇壳聚糖和聚多巴胺功能化的RhNPs（Rh@GCS）被开发用于治疗耐药SSTI。RhNP对耐甲氧西林金黄色葡萄球菌（MRSA）和耐银MRSA表现出良好的抗菌活性。修饰后的Rh@GCS具有增强的抗菌活性,可通过增加细胞膜通透性直接杀灭多种耐药菌,包括革兰阳性MRSA和革兰阴性多重耐药大肠埃希菌和铜绿假单胞菌。此外，Rh@GCS在MRSA诱导的SSTI小鼠模型中有效抑制细菌生长并促进皮损愈合。这些结果表明，Rh@GCS是一种有前途的非抗生素抗微生物剂，用于治疗耐药的SSTI。本文受版权保护。保留所有权利。
